Raymond James Trust’s RxSight RXST Stock Holding History

Raymond James Trust’s Portfolio RXST Stock Details RXST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-3,434	Closed	-$207K	–	1344
2024 Q2	$207K	Buy	+3,434	New	+$196K	﹤0.01%	1174

Other funds holding RXST

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Raymond James Trust's RXST Position: Q3 2024 in Review

Raymond James Trust sold out of RxSight (RXST) in Q3 2024, closing a stake of 3,434 shares — an estimated $207K sold.

Raymond James Trust first reported a position in RXST in Q2 2024 and held it in 1 quarter. The position peaked at $207K in Q2 2024. 214 funds tracked by Wall St. Rank hold RXST as of Q3 2024.

Raymond James Trust reported no remaining RxSight position as of Q3 2024 after selling out during the quarter.
Raymond James Trust sold 3,434 RxSight shares in Q3 2024, an estimated $207K.
Raymond James Trust first reported a position in RxSight in Q2 2024 and held it in 1 quarter.
Raymond James Trust's RxSight position peaked at $207K in Q2 2024.
214 funds tracked by Wall St. Rank held RxSight as of Q3 2024.

Based on Raymond James Trust's 13F filing for Q3 2024, filed 12 Nov 2024.